Published on Aug 4, 2017
Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are phasing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
